Skip to main content

Advertisement

Log in

Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This case presents a patient with hypertrophic osteoarthropathy of the lower extremities that developed secondary to congenital cyanotic heart disease. The major clinical manifestation was severe bilateral leg pain. The pain that was debilitating in nature completely resolved following a single administration of 60 mg pamidronate. Hypertrophic osteoarthropathy (HOA) is an acquired, uncommon disorder of obscure etiology. It has been described mainly in association with chronic suppurative pulmonary diseases, bronchogenic carcinoma and lung metastases, cystic fibrosis, and cyanotic congenital malformations of the heart.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2 a

Similar content being viewed by others

References

  1. Semple T, McCluskie RA (1955) Generalized hypertrophic osteoarthropathy in association with bronchial carcinoma. Br Med J 1:754–759

    Google Scholar 

  2. Garske LA, Bell SC (2002) Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 121:1363–1364

    Article  PubMed  Google Scholar 

  3. Martinez-Lavin M (1992) Cardiogenic hypertrophic osteoarthropathy. Clin Exp Rheumatol 10 [Suppl 7]:19–21

  4. Pineda C, Fonseca C, Martinez-Lavin M (1990) The spectrum of soft tissue and skeletal abnormalities of hypertrophic osteoarthropathy. J Rheumatol 17:626–632

    CAS  PubMed  Google Scholar 

  5. Reid IR (2003) Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 15:458–463

    Article  CAS  PubMed  Google Scholar 

  6. Suzuma T, Sakurai T, Yoshimura G, Umemura T, Tamaki T, Yoshimasu T, Naito (2001) Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs 12:731–734

    Article  CAS  PubMed  Google Scholar 

  7. Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C (1996) Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 15:435–439

    CAS  PubMed  Google Scholar 

  8. Silveira LH, Martinez-Lavin M, Pineda C, Fonseca MC, Navarro C, Nava A (2000) Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 18:57–62

    Google Scholar 

  9. Abe Y, Kurita S, Ohkubo Y, et al. (2002) A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 22:3485–3488

    PubMed  Google Scholar 

  10. Luckman SP, Hughes DE, Coxon FP, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589

    CAS  PubMed  Google Scholar 

  11. Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108–111

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Howard Amital.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amital, H., Applbaum, Y.H., Vasiliev, L. et al. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 23, 330–332 (2004). https://doi.org/10.1007/s10067-004-0941-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-004-0941-4

Keywords

Navigation